title: Thyrotropin-secreting pituitary adenoma in an adolescent boy: challenges in management.
abstract: Thyrotropinomas tend to be aggressive, invasive tumors that are difficult to resect because of their marked fibrosis and their proximity to vital structures such as the optic chiasm. The latter characteristic also limits the use of radiation therapy. In the few cases reported of children younger than 18 years whose thyrotropinomas were treated surgically, the results were disappointing. We present here the case of a 16-year-old boy with a thyrotropin-secreting pituitary macroadenoma who underwent partial resection via a transsphenoidal approach and was left with significant residual tumor and continued hyperthyroidism. He subsequently received 4 years of long-acting release somatostatin therapy, during which he has remained euthyroid without requiring antithyroid medication. To our knowledge, this is thus far the longest duration of somatostatin therapy in the pediatric age group. This regimen also achieved a decrease in compression of the optic nerve and prevented further tumor growth. We review here the current literature on somatostatin analog treatment including molecular mechanisms and promising new treatment modalities, such as the heterodimerization of dopamine and somatostatin receptors. We conclude that this has been a useful adjuvant treatment for our adolescent patient.
authors.affiliation: Department of Pediatrics, New York University Medical Center, New York, NY 10016, USA. marion.kessler@nyumc.org.
authors.forename: Marion
authors.initials: M
authors.lastname: Kessler
authors.forename: Raphael
authors.initials: R
authors.lastname: David
authors.forename: Melissa
authors.initials: M
authors.lastname: Pawelczak
authors.forename: Anat
authors.initials: A
authors.lastname: Hanono
authors.forename: Bina
authors.initials: B
authors.lastname: Shah
mesh_terms: D000236:Adenoma / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D000293:Adolescent; D003131:Combined Modality Therapy; D006801:Humans; D006980:Hyperthyroidism / Q000209:etiology*; D008297:Male; D018365:Neoplasm, Residual; D019635:Neurosurgical Procedures / Q000379:methods; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism / Q000628:therapy; D013004:Somatostatin / Q000627:therapeutic use*; D013972:Thyrotropin / Q000378:metabolism*
chemical_list: D013004:Somatostatin; D013972:Thyrotropin